Compare Illumina, Inc. (ILMN) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Qurate Retail Inc Series A — how do they compare? Illumina, Inc. trades at $191.6 (market cap $27.94B), while Qurate Retail Inc Series A trades at $0.04 (market cap $698.27K). The key difference: Illumina, Inc. is far larger — about 40013.2× Qurate Retail Inc Series A's market cap, and Illumina, Inc. is trading nearer its 52-week high, Qurate Retail Inc Series A nearer its low. Which is the better fit depends on your goals.
| ILMN | QVCAQ | |
|---|---|---|
Market Cap | $27.94B | $698.27K |
Sector | Health | Consumer Cyclical |
52-Week High | $194.33 | $15.03 |
52-Week Low | $91.00 | $0.05 |
Enterprise Value | $29.33B | $4.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
QVCAQ trades at $0.05, down 14.68% today, reflecting severe financial distress with negative equity and consecutive annual losses. The stock shows a bearish technical signal, with most moving averages indicating sell pressure. Recent cash flow improvements stem from financing activities, not operations. The company celebrated 40 years of innovation with a TikTok Shop event, but fundamentals remain weak.
Outlook is highly risky due to persistent net losses, declining revenue, and negative shareholder equity. Investment opportunity is minimal without a turnaround in profitability. Key risks include high debt burden, competitive pressures in retail, and inability to achieve sustained earnings growth. Investors should avoid until operational stability is demonstrated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →
